$3.3m · Series A · Healthtech · Edinburgh, UK
Edinburgh-based Bioliberty has raised a $3.3m Series A extension from TGH Ventures, Ballad Ventures, 25M Health and Whiterock. The financing follows the company’s earlier Series A work on soft-robotic rehabilitation technology.
Assistance that can move with the patient
Bioliberty develops wearable robotics intended to support hand and upper-limb rehabilitation. Its approach combines soft actuation with sensing and software so patients can practise repeated movements outside a therapist’s direct one-to-one supervision.
Rehabilitation is constrained by time and intensity: recovery often requires many repetitions, while clinical teams have limited capacity. A wearable system can extend practice into the home and generate data on how a patient is progressing. It does not replace clinical judgement; the value depends on whether therapists can use the measurements to adjust treatment and whether patients continue using the device correctly.
The extension must convert engineering into evidence
Bioliberty emerged from the University of Edinburgh ecosystem and has previously raised capital to move its soft-robotic glove toward clinical use. The new investors add funding for the next stage, but medical-device adoption requires more than a functional prototype.
The company needs to demonstrate safety, reliable fit across different users and meaningful outcomes in real rehabilitation pathways. It must also fit procurement and reimbursement models that can be slow even when clinicians see potential. The Series A extension gives Bioliberty more room to build that evidence and industrialise the product; the decisive milestone is whether repeated use improves recovery in a way providers can measure and pay for.
